Physician profile
Clint C Moss
NPI 1578726352
$5,708.67
in general payments reported to CMS, 2019-2025
25 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $158 · 2021: $760 · 2022: $946 · 2023: $619 · 2024: $928 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.97 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.92 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $927.46 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $682.25 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $542.14 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $436.62 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $429.35 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $260.38 | 2019-2022 | |
| Ucb, INC. | $133.37 | 2024-2025 | Bimzelx |
| Pfizer INC. | $110.59 | 2022-2025 | |
| Galderma Laboratories, L.P. | $104.29 | 2019-2025 | Nemluvio |
| Almirall LLC | $91.23 | 2021-2025 | Klisyri |
| Amgen INC. | $79.52 | 2021-2024 | Otezla |
| Genentech USA, INC. | $64.89 | 2019-2024 | Erivedge |
| Genzyme Corporation | $64.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $55.76 | 2022-2025 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $36.52 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.20 | 2019 | |
| Mayne Pharma Commercial LLC | $30.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2025 | Spevigo |
| Allergan, INC. | $29.67 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $25.26 | 2024 | Idacio |
| Epi Health, LLC | $24.02 | 2022 | |
| Dusa Pharmaceuticals, INC. | $22.23 | 2019 | |
| Dermira, INC. | $21.02 | 2019 | |
| Merck Sharp & Dohme LLC | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.